to OHR Pharmaceutical
Ohr Pharmaceutical Inc. (OTCBB:OHRP) is a pharmaceutical company dedicated to the development of first-in-class drugs for under-served therapeutic needs.
OHR is focused on the development of novel therapeutics for the treatment of serious and unmet medical needs. Our lead compounds include OHR/AVR 118 for the treatment of Cancer Cachexia and Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet-AMD) and other ophthalmic neovascularization disorders. Cancer Cachexia, the syndrome of body wasting, is characterized by symptoms of loss of appetite and body weight, fatigue, and loss of muscle mass. It is a debilitating condition which affects many late-stage cancer patients and greatly diminishes their quality of life. Wet-AMD is a leading cause of vision loss and blindness in the elderly population, affecting over 1.75 million patients in the United States alone. The promise shown by OHR Pharmaceutical's product pipeline offers a new ray of hope to patients suffering from these devastating diseases.